Patients were randomized to receive placebo , cariprazine @ mg/d , cariprazine @ mg/d , cariprazine @ mg/d , or risperidone @ mg/d ( for assay sensitivity ) for @ weeks of double-blind treatment and @ weeks of safety follow-up .